These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 27514840)
41. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer. Kwong A; Chen J; Shin VY; Ho JC; Law FB; Au CH; Chan TL; Ma ES; Ford JM Cancer Genet; 2015 Sep; 208(9):448-54. PubMed ID: 26271414 [TBL] [Abstract][Full Text] [Related]
42. Variability in Cancer Risk with BRCA Mutations. Cancer Discov; 2015 Jul; 5(7):OF16. PubMed ID: 25952264 [No Abstract] [Full Text] [Related]
43. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing. Cohen PA; Nichols CB; Schofield L; Van Der Werf S; Pachter N Int J Gynecol Cancer; 2016 Jun; 26(5):892-7. PubMed ID: 27051053 [TBL] [Abstract][Full Text] [Related]
44. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Murray ML; Cerrato F; Bennett RL; Jarvik GP Genet Med; 2011 Dec; 13(12):998-1005. PubMed ID: 21811163 [TBL] [Abstract][Full Text] [Related]
45. Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation. Hull LE; Haas JS; Simon SR Am J Prev Med; 2018 Feb; 54(2):221-228. PubMed ID: 29241717 [TBL] [Abstract][Full Text] [Related]
46. BRCA1 and BRCA2 mutations in a South American population. Jara L; Ampuero S; Santibáñez E; Seccia L; Rodríguez J; Bustamante M; Martínez V; Catenaccio A; Lay-Son G; Blanco R; Reyes JM Cancer Genet Cytogenet; 2006 Apr; 166(1):36-45. PubMed ID: 16616110 [TBL] [Abstract][Full Text] [Related]
47. Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach. Moss HA; Samimi G; Havrilesky LJ; Sherman ME; Myers ER Genet Epidemiol; 2018 Feb; 42(1):117-122. PubMed ID: 29193313 [TBL] [Abstract][Full Text] [Related]
48. Identification and management of familial breast cancer in Austria. Singer CF; Tan YY; Rappaport C Horm Mol Biol Clin Investig; 2017 Nov; 32(2):. PubMed ID: 29190211 [TBL] [Abstract][Full Text] [Related]
49. Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities. Augustyn AM; Agostino NM; Namey TL; Nair S; Martino MA Breast Cancer Res Treat; 2011 Sep; 129(2):629-34. PubMed ID: 21607582 [TBL] [Abstract][Full Text] [Related]
50. Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers. Kim SH; Hwang HK; Lee WJ; Kang CM Pancreatology; 2021 Apr; 21(3):544-549. PubMed ID: 33612442 [TBL] [Abstract][Full Text] [Related]
51. Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. Sabatier R; Lavit E; Moretta J; Lambaudie E; Noguchi T; Eisinger F; Cherau E; Provansal M; Livon D; Rabayrol L; Popovici C; Charaffe-Jauffret E; Sobol H; Viens P Fam Cancer; 2016 Oct; 15(4):497-506. PubMed ID: 26833043 [TBL] [Abstract][Full Text] [Related]
52. Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers? Semple J; Metcalfe KA; Lubinski J; Huzarski T; Gronwald J; Armel S; Lynch HT; Karlan B; Foulkes W; Singer CF; Neuhausen SL; Eng C; Iqbal J; Narod SA; Breast Cancer Res Treat; 2015 Nov; 154(1):163-9. PubMed ID: 26467043 [TBL] [Abstract][Full Text] [Related]
53. Cancer worry among Norwegian male BRCA1/2 mutation carriers. Strømsvik N; Råheim M; Gjengedal E Fam Cancer; 2011 Sep; 10(3):597-603. PubMed ID: 21603983 [TBL] [Abstract][Full Text] [Related]
54. The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety. Sermijn E; Delesie L; Deschepper E; Pauwels I; Bonduelle M; Teugels E; De Grève J Fam Cancer; 2016 Apr; 15(2):155-62. PubMed ID: 26748927 [TBL] [Abstract][Full Text] [Related]
55. Interventions to support decision making in people considering germline genetic testing for BRCA 1/2 pathogenic and likely pathogenic variants: A scoping review. Pozzar RA; Seven M J Genet Couns; 2024 Apr; 33(2):392-401. PubMed ID: 37328917 [TBL] [Abstract][Full Text] [Related]
56. Further development and evaluation of a breast/ovarian cancer genetics referral screening tool. Bellcross C Genet Med; 2010 Apr; 12(4):240. PubMed ID: 20395744 [No Abstract] [Full Text] [Related]
57. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer. Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249 [TBL] [Abstract][Full Text] [Related]
58. BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high risk families. Sinilnikova OM; Mazoyer S; Bonnardel C; Lynch HT; Narod SA; Lenoir GM Fam Cancer; 2006; 5(1):15-20. PubMed ID: 16528604 [TBL] [Abstract][Full Text] [Related]
59. Women's Health Issues for BRCA Mutation Carriers. Sabatini ME; Ellisen LW Am Soc Clin Oncol Educ Book; 2016; 35():14-7. PubMed ID: 27249681 [No Abstract] [Full Text] [Related]
60. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. Wood ME; Garber JE; Isaacs C; Masood S; Bedrosian I; Tung N; Chun J; Schnabel FR; Arun BK; Breast J; 2019 Jul; 25(4):575-577. PubMed ID: 31280501 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]